A dose-response study of phenylephrine in critically ill, septic surgical patients

AbstractObjective: To determine the response of haemodynamic and oxygen-transport parameters to phenylephrine in a dose-response fashion in septic non-hypotensive, vasodilated surgical intensive care unit (ICU) patients. Design: Prospective study. Setting: Surgical ICU of a tertiary care, university medical centre. Patients: Ten septic non-hypotensive, vasodilated surgical ICU patients. Interventions: Routine ICU monitoring, including pulmonary and radial artery catheters. Measurements: Haemodynamic and oxygen-transport measurements were taken at baseline and during therapy. Phenylephrine was infused intravenously for 3 h at progressively increasing doses of 0.5, 1.0, 2.0, 3.0, 4.0, and 8.0 μg · kg−1 · min−1 at 30-min intervals. Measurements were taken after each dose. Results: Mean arterial pressure (MAP) and systemic vascular resistance (SVRI) increased linearly with phenylephrine dose. Cardiac index and pulmonary artery occlusion pressures did not change. Statistically significant changes were observed in heart rate, MAP, stroke index, and systemic and pulmonary vascular resistance. Eight patients had a clinically significant increase (>15%) in oxygen consumption (VO2I). Oxygen delivery (D2OI) increased in only three patients. Serum lactate concentrations were unchanged or lower at the end of the study in all eight pateints, who displayed a 15% increase in VO2I. Conclusions: Treatment with phenylephrine increased expected haemodynamic parameters in a linear fashion; however, clinical changes in VO2I occurred at variable doses. Dose-response trials are needed to determine the optimal dose of phenylephrine. Further study is needed to evaluate the clinical effects of phenylephrine in septic patients.

[1]  M. Weil,et al.  Cellular oxygen metabolism during sepsis and shock. The relationship of oxygen consumption to oxygen delivery. , 1988, JAMA.

[2]  Y. Shimada,et al.  Circulatory responses to afterloading with phenylephrine in hyperdynamic sepsis , 1982, Critical care medicine.

[3]  C. Hinds,et al.  Response of critically ill patients to treatment aimed at achieving supranormal oxygen delivery and consumption. Relationship to outcome. , 1993, Chest.

[4]  J. Dasta.  Norepinephrine in Septic Shock: Renewed Interest in an Old Drug , 1990, DICP : the annals of pharmacotherapy.

[5]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[6]  M. Palazzo,et al.  Use of survivors' cardiorespiratory values as therapeutic goals in septic shock. , 1991, Critical care medicine.

[7]  P Leppard,et al.  Epinephrine as an inotropic agent in septic shock: A dose‐profile analysis , 1993, Critical care medicine.

[8]  L. Papazian,et al.  Norepinephrine or Dopamine for the Treatment of Hyperdynamic Septic Shock , 1993 .

[9]  P. Marik,et al.  The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. , 1994, JAMA.

[10]  Elevation of systemic oxygen delivery in the treatment of critically ill patients , 1995 .

[11]  W. Shoemaker,et al.  Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. , 1988, Chest.

[12]  J. Takala,et al.  Regional blood flow and oxygen transport in septic shock , 1993, Critical care medicine.

[13]  M. Pinaud,et al.  Norepinephrine therapy has no deleterious renal effects in human septic shock. , 1989, Critical care medicine.

[14]  J. L. Gall,et al.  APACHE II--a severity of disease classification system. , 1986, Critical care medicine.

[15]  J. Reves,et al.  Time Course and Hemodynamic Effects of Alpha‐1‐Adrenergic Bolus Administration in Anesthetized Patients with Myocardial Disease , 1989, Anesthesia and analgesia.

[16]  C. Chopin,et al.  Prognostic value of the dobutamine test in patients with sepsis syndrome and normal lactate values: A prospective, multicenter study , 1993, Critical care medicine.

[17]  H. Eichler,et al.  Effect of Ketanserin on Phenylephrine‐Dependent Changes in Splanchnic Hemodynamics and Systemic Blood Pressure in Healthy Subjects , 1985, Journal of cardiovascular pharmacology.

[18]  R. Raper.  ORGAN BLOOD FLOW IN HIGH OUTPUT NORMOTENSIVE SEPSIS , 1987 .

[19]  J. Edwards,et al.  Reversal of intractable septic shock with norepinephrine therapy. , 1988, Critical care medicine.

[20]  W. Shoemaker,et al.  Therapy of shock based on pathophysiology, monitoring, and outcome prediction , 1990, Critical care medicine.

[21]  P. T. Phang,et al.  The oxygen delivery/consumption controversy. Approaches to management of the critically ill. , 1994, American journal of respiratory and critical care medicine.

[22]  K. Starke,et al.  Alpha 1- and alpha 2-adrenoceptors: pharmacology and clinical implications. , 1981, Journal of cardiovascular pharmacology.